New ADC Drug Shows Promise in Lung Cancer With Key Biomarker Clues
A phase 2 trial of datopotamab deruxtecan in 100 NSCLC patients reveals a 26% response rate and critical resistance biomarkers.
Summary
A French multicenter phase 2 study tested datopotamab deruxtecan, an antibody-drug conjugate targeting TROP2, in 100 previously treated patients with advanced non-small cell lung cancer. The drug achieved a 26% objective response rate and a median progression-free survival of 3.6 months, with better outcomes in non-squamous tumors. Crucially, the study identified potential biomarkers of resistance — specifically, lack of TROP2 cytoplasmic staining and early activation of DNA repair pathways — while immune pathway activation was linked to better responses. These findings could help oncologists identify which patients are most likely to benefit from this class of therapy, though validation in larger phase 3 trials is needed before clinical adoption.
Detailed Summary
Antibody-drug conjugates represent one of the most rapidly evolving frontiers in oncology, yet a persistent challenge has been the absence of validated biomarkers to predict which patients will respond. This gap leads to unnecessary toxicity and missed therapeutic opportunities, making the ICARUS-LUNG01 study particularly timely.
The trial enrolled 100 pretreated patients with advanced non-small cell lung cancer across multiple French centers. All participants received datopotamab deruxtecan (Dato-DXd), a TROP2-directed ADC that delivers a cytotoxic payload directly to cancer cells expressing the TROP2 surface protein. The study was designed not only to assess clinical outcomes but also to conduct longitudinal translational analyses — collecting tumor samples at baseline and during treatment to interrogate biological mechanisms.
The drug achieved an objective response rate of 26%, with a median progression-free survival of 3.6 months. Non-squamous histology tumors responded better than squamous tumors, consistent with prior observations in this drug class. These efficacy numbers are modest but meaningful in a heavily pretreated population where options are limited.
The most scientifically significant findings were mechanistic. Resistance to Dato-DXd appeared associated with absent TROP2 cytoplasmic staining and early upregulation of DNA repair pathways, suggesting tumors can rapidly adapt to evade the drug's mechanism. Conversely, activation of immune-related pathways at baseline correlated with treatment response, raising the possibility that immune-hot tumors may be particularly susceptible.
These biomarker signals, if validated in phase 3 trials, could transform patient selection for ADC therapy in lung cancer. However, the study's modest sample size, single-arm design, and reliance on abstract-level reporting limit definitive conclusions. Prospective biomarker-driven trials will be essential to translate these findings into clinical practice.
Key Findings
- Dato-DXd achieved a 26% objective response rate in pretreated advanced NSCLC patients across 100 participants.
- Median progression-free survival was 3.6 months, with non-squamous tumors showing greater benefit than squamous tumors.
- Lack of TROP2 cytoplasmic staining and early DNA repair pathway activation were linked to drug resistance.
- Activation of immune-related pathways at baseline was associated with better treatment response.
- Findings require phase 3 validation before biomarkers can guide clinical patient selection.
Methodology
ICARUS-LUNG01 is a prospective, multicenter, single-arm phase 2 trial enrolling 100 pretreated advanced NSCLC patients treated with Dato-DXd. The study integrated clinical outcome assessment with longitudinal translational tumor analyses at baseline and on-treatment timepoints. No comparator arm was included, limiting causal inference.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, limiting depth of analysis. The single-arm phase 2 design without a control group prevents definitive efficacy conclusions. The sample size of 100 patients is insufficient to validate biomarkers for clinical use without phase 3 confirmation.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.